ReviewClinical ophthalmology (Auckland, N.Z.)2025
Cystoid Macular Edema Following Rhegmatogenous Retinal Detachment Repair Surgery: Incidence, Pathogenesis, Risk Factors and Treatment.
Review in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To review the incidence, risk factors, and treatments for cystoid macular edema (CME) following rhegmatogenous retinal detachment (RRD) repair surgery. Methods: A comprehensive literature search was conducted across multiple databases. Relevant studies published within the last 20 years were selected and reviewed. Results: The incidence of CME following RRD repair ranges from 6% to 36%, with higher rates associated with silicone oil tamponade. Key risk factors include recurrent RRD, pre-existing proliferative vitreoretinopathy, older age, and post-RRD cataract surgery. Treatment options primarily focus on anti-inflammatory approaches, with topical NSAIDs and corticosteroids as first-line treatments. For persistent cases, intravitreal corticosteroid injections, particularly dexamethasone implants, have shown potential. Conclusion: CME remains a significant complication following RRD repair, impacting visual recovery. While various treatment options exist, management of persistent CME remains challenging. Better understanding of the underlying mechanisms of CME is required to develop more effective treatment strategies, particularly for cases resistant to current therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.